About:
Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.